NCT07234825 Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
| NCT ID | NCT07234825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kate Farms Inc |
| Condition | Eosinophilic Esophagitis (EoE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2026-03-18 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.
Eligibility Criteria
Inclusion Criteria: * Pediatric patients 1 year to 21 of age presenting with chronic symptoms of dysphagia, odynophagia, vomiting or heartburn, chronic abdominal pain, weight loss, picky eating, to outpatient gastroenterology clinic and are planning to undergo EGD for evaluation. Exclusion Criteria: * Non-English-Speaking Subjects, adults unable to consent, wards of the state, pregnant women, and prisoners will be excluded from the study. * Patients with autoimmune conditions such as inflammatory bowel disease. Patients with prior esophageal or intestinal surgeries. * Patients with history of eating disorders or ARFID. * Patients with fistulizing or fibrotic disease on baseline EGD. * Patients who have received proton pump inhibitory therapy in the past month.
Contact & Investigator
Michael Pickens, DO
PRINCIPAL INVESTIGATOR
Seattle Children's Hospital
Frequently Asked Questions
Who can join the NCT07234825 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 21 Years, studying Eosinophilic Esophagitis (EoE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07234825 currently recruiting?
Yes, NCT07234825 is actively recruiting participants. Contact the research team at Danny.Gagucas@seattlechildrens.org for enrollment information.
Where is the NCT07234825 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07234825 clinical trial?
NCT07234825 is sponsored by Kate Farms Inc. The principal investigator is Michael Pickens, DO at Seattle Children's Hospital. The trial plans to enroll 36 participants.